

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported):

**May 21, 2020**

**Ra Medical Systems, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-38677**  
(Commission  
File Number)

**38-3661826**  
(IRS Employer  
Identification No.)

**2070 Las Palmas Drive  
Carlsbad, California 92011**  
(Address of principal executive offices, including zip code)

**(760) 804-1648**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Common Stock, par value \$0.0001 per share	RMED	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**

On May 21, 2020, Ra Medical Systems, Inc. (the “Company”) received written notice from The New York Stock Exchange (the “NYSE”) indicating that the Company is no longer in compliance with the NYSE’s continued listing standards as set forth in Section 802.01C of the NYSE’s Listed Company Manual, which requires listed companies to maintain an average closing share price of at least \$1.00 over a consecutive 30 trading-day period.

In accordance with Section 802.01C of the NYSE’s Listed Company Manual, the Company has a period of six months, to regain compliance with the average closing share price requirement. In response to the COVID-19 pandemic, the NYSE is tolling compliance periods until at least June 30, 2020. If such tolling period is not further extended, the Company must regain compliance by December 31, 2020. To regain compliance, on the last trading day of any calendar month during the cure period, the Company’s common stock must have (i) a closing price of at least \$1.00 per share and (ii) an average closing price of at least \$1.00 per share over the 30-trading day period ending on the last trading day of such month. If the Company is unable to regain compliance, the NYSE will initiate procedures to suspend and delist the Company’s common stock.

The notification has no immediate effect on the listing of the Company’s common stock, which will continue to be listed and traded on the NYSE during the cure period, subject to the Company’s compliance with the other listing requirements of the NYSE. The Company’s common stock will continue to trade under the symbol “RMED” but will have an added designation of “.BC” to indicate the status of the common stock as “below compliance” with the NYSE’s continued listing standards. The “.BC” indicator will be removed at such time as the Company regains compliance.

The Company intends to monitor the closing price of its common stock and consider implementing available options to regain compliance with the average closing share price requirement.

A copy of the Company’s press release announcing the notice of non-compliance with the average closing share price requirement is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

**Item 9.01. Financial Statements and Exhibits.**

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#"><u>Press release, issued May 22, 2020</u></a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**RA MEDICAL SYSTEMS, INC.**

Date: May 22, 2020

By: /s/ Daniel Horwood

Daniel Horwood

General Counsel and Secretary



## Ra Medical Systems Receives Continued Listing Standard Notice from the NYSE

**CARLSBAD, Calif. (May 22, 2020)** - Ra Medical Systems, Inc. ("Ra Medical") (NYSE: RMED), a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases, today announced receipt of written notice from The New York Stock Exchange (the "NYSE") indicating that Ra Medical is no longer in compliance with the NYSE's continued listing standards as set forth in Section 802.01C of the NYSE's Listed Company Manual, which requires listed companies to maintain an average closing share price of at least \$1.00 over a consecutive 30 trading-day period.

In accordance with Section 802.01C of the NYSE's Listed Company Manual, Ra Medical has a period of six months, to regain compliance with the average closing share price requirement. In response to the COVID-19 pandemic, the NYSE is tolling compliance periods until at least June 30, 2020. If such tolling period is not further extended, Ra Medical must regain compliance by December 31, 2020. To regain compliance, on the last trading day of any calendar month during the cure period, Ra Medical's common stock must have (i) a closing price of at least \$1.00 per share and (ii) an average closing price of at least \$1.00 per share over the 30-trading day period ending on the last trading day of such month. If Ra Medical is unable to regain compliance, the NYSE will initiate procedures to suspend and delist Ra Medical's common stock.

The notification has no immediate effect on the listing of Ra Medical's common stock, which will continue to be listed and traded on the NYSE during the cure period, subject to Ra Medical's compliance with the other listing requirements of the NYSE. Ra Medical's common stock will continue to trade under the symbol "RMED" but will have an added designation of ".BC" to indicate the status of the common stock as "below compliance" with the NYSE's continued listing standards. The ".BC" indicator will be removed at such time as Ra Medical regains compliance.

Ra Medical intends to monitor the closing price of its common stock and consider implementing available options to regain compliance with the average closing share price requirement.

### About Ra Medical Systems

Ra Medical Systems commercializes excimer lasers and catheters for the treatment of vascular and dermatological diseases. In May 2017, the DABRA laser system and single-use DABRA catheter received FDA 510(k) clearance in the U.S. as a device for crossing chronic total occlusions, or CTOs, in patients with symptomatic infrainguinal lower extremity vascular disease with an intended use for ablating a channel in occlusive peripheral vascular disease. Pharos excimer laser system is FDA-cleared and is used as a tool in the treatment of psoriasis, vitiligo, atopic dermatitis, and leukoderma. DABRA and Pharos are both based on Ra Medical's core excimer laser technology platform and deploy similar mechanisms of action. Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, Calif. The vertically integrated facility is ISO 13485 certified and is licensed by the state of California to manufacture sterile, single-use catheters in controlled environments.

### Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Ra Medical's future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these words or other similar terms or expressions that concern Ra Medical's future

---

expectations, strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to, statements regarding Ra Medical's compliance with the average closing share price requirement and Ra Medical's continued listing on the NYSE. The forward-looking statements included in this press release are subject to a number of material risks and uncertainties, including but not limited to the risks described under the heading "Risk Factors" in Ra Medical's Annual Report on Form 10-K for the year ended December 31, 2019, Quarterly Report on Form 10-Q for the three months ended March 31, 2020, and other filings with the SEC. The forward-looking statements in this press release are based on information available to Ra Medical as of the date hereof, and Ra Medical disclaims any obligation to update any forward-looking statements, except as required by law.

## **Contacts**

### At the Company:

Jeffrey Kraws  
President, Ra Medical Systems  
760-496-9008  
jkraws@ramed.com

### Investors and Media:

LHA Investor Relations  
Jody Cain  
310-691-7100  
jcain@lhai.com

# # #